SEC Form 4 · accession 0001415889-17-001265
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn Baity
Officer — EVP AND GC
Period of report
Jul 20, 2017
Accepted (ET)
Jul 21, 2017 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 20, 2017 | M | 28,097 | $1.62 | A | 109,253 | D | |
| Common Stock | Jul 20, 2017 | S | 38,097 | $30.00 | D | 71,156 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.62 | Jul 20, 2017 | M | 28,097 | D | — | Mar 24, 2021 | Common Stock | 28,097 | 28,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
- F225% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.